Seegene Germany – Multiplex PCR for modern infection diagnostics
Seegene Germany GmbH, based in Düsseldorf, is the German subsidiary of the global company Seegene Inc. headquartered in Seoul, South Korea. Since its foundation in September 2017, Seegene Germany has been driving forward the development, approval and marketing of innovative in vitro diagnostics in Germany – with the aim of taking molecular diagnostics to a new level.
Seegene Inc. is a leading international company in the field of molecular diagnostics, focusing on multiplex real-time PCR technologies. These are based on the patented DPO™, TOCE™ and MuDT™ platforms and enable the simultaneous detection of up to 15 pathogens in a single test run – efficiently, accurately and reliably. Whether virus, bacterium or parasite: Seegene's multiplex PCR tests cover a wide range of infectious agents, including pandemic challenges such as SARS-CoV-2 or multi-resistant germs.
Seegene not only supplies assays, but also offers a complete diagnostic solution – from DNA extraction and automated PCR analysis to intelligent data evaluation. This enables laboratories, clinics and research institutions worldwide to benefit from an optimised workflow with the highest quality standards.
More than 60 employees in Düsseldorf work across disciplines to quickly implement diagnostic innovations in line with market needs. Clinical relevance is always the focus: with each product generation, Seegene contributes to the early and comprehensive detection of infections, thereby enabling more targeted therapies.
Seegene continuously invests in research, technology and automation to steadily improve laboratory efficiency and diagnostic reliability. With a strong international network, technical excellence through patented technologies and a clear vision of tomorrow's requirements, Seegene sets standards in molecular infection diagnostics.
Find out more at: www.seegene.de
